共 109 条
[1]
Solomon B(2009)ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer J Thorac Oncol 4 1450-1454
[2]
Varella-Garcia M(2014)First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med 371 2167-2177
[3]
Camidge DR(2009)Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 4247-4253
[4]
Solomon BJ(2010)Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression Mol Cancer 9 188-2394
[5]
Mok T(2013)Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2385-1133
[6]
Kim DW(2016)Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer Cancer Discov 6 1118-43
[7]
Shaw AT(2012)Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers Sci Transl Med 4 120ra17-1888
[8]
Yeap BY(2014)Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer Lung Cancer 83 37-322
[9]
Mino-Kenudson M(2015)Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases J Clin Oncol 33 1881-242
[10]
Zhang X(2015)Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden J Med Econ 18 312-886